摘要
运用网络药理学结合分子对接技术探讨芪胶升白胶囊治疗白细胞减少症的作用机制.通过中药系统药理学数据库与分析平台数据库(TCMSP)和SwissTargetPrediction数据库综合相关文献报道获得芪胶升白胶囊功能靶标,在GeneCards数据库中获取白细胞减少症的治疗靶点,并对两者取交集靶点后,在DAVID数据库中进行基因本体论(GO)功能和京都基因与基因组百科全书(KEGG)通路富集分析.收集我院住院期间使用芪胶升白胶囊的白细胞减少症患者,比较使用前、后白细胞水平变化.采用动物实验验证网络药理学预测芪胶升白胶囊治疗白细胞减少症的核心靶点.芪胶升白胶囊与白细胞减少症交集靶点有124个,GO富集分析主要在基因表达调控、凋亡过程、细胞增殖等方面,KEGG富集分析主要在PI3K-Akt信号、细胞衰老、TNF信号通路、细胞凋亡、IL-17信号通路、NF-kappa B信号通路等方面.通过“药物-活性成分-靶点-通路-疾病”网络图分析发现,槲皮素、木犀草素、金雀异黄素、山柰酚、β-谷甾醇、非瑟酮、甘草素、8-异戊烯-山奈酚、花萼素、β-胡萝卜素作为芪胶升白胶囊的核心活性成分,可作用于PTGS2、RXRA、PIK3CG、CDK2、TNF、IL6、AKT1、CASP3、MAPK1、BCL2关键靶点,发挥治疗白细胞减少症的作用.临床研究发现,芪胶升白胶囊可明显升高住院期间白细胞减少症患者的白细胞水平,有效率达60.00%.动物实验发现,芪胶升白胶囊可明显升高小鼠白细胞水平(P<0.05),降低外周血TNF-α、IL-6水平(P<0.05).结果表明,芪胶升白胶囊中活性成分可作用于TNF-α、IL-6等关键靶点,参与免疫炎症等通路发挥治疗白细胞减少症的作用.
This study aims to explore the mechanism of Qijiaoshengbai capsule in treating leukopenia by using network pharmacology and molecular docking technology.The functional target of Qijiaoshengbai capsule was obtained through TCMSP,Swiss TargetPrediction database and relevant literature reports.Then,therapeutic targets for leukopenia were obtained from the GeneCards database.After the intersection of the functional target of Qijiaoshengbai capsule and the therapeutic target of leukopenia,the gene ontological function(GO)and kyoto encyclopedia of genes and genomes(KEGG)were performed in the DAVID database.The patients with leukopenia who used Qijiaoshengbai capsule during hospitalization in our hospital were recruited,and the changes of leukocyte level before and after taking Qijiaoshengbai capsule were determined.The animal experiment was used to verify the core target of Qijiaoshengbai capsule predicted by the network pharmacology in the treatment of leukopenia.There were 124 intersection targets between Qijiaoshengbai capsule and leukopenia.GO enrichment analysis mainly focused on gene expression regulation,apoptosis process and cell proliferation,and KEGG enrichment analysis mainly focused on PI3K-Akt signal,cell senescence,TNF signaling pathway,cell apoptosis,IL-17 signaling pathway and NF-kappa B signaling pathway.Through the network diagram analysis of“drug-active ingredient-target-pathway-disease”,quercetin,luteolin,genistein,kaempferol,β-sitosterol,fisetin,liquiritigenin,8-isopentene kaempferol,calycosin andβ-carotene were found to be the core active ingredients of Qijiaoshengbai capsule,which can act on the key targets of PTGS2,RXRA,PIK3CG,CDK2,TNF,IL6,AKT1,CASP3,MAPK1,BCL2,and play a role in the treatment of leukopenia.The clinical study found that Qijiaoshengbai capsule could significantly increase the level of white blood cells with an effective rate of 60.00%in the patients with leukopenia.Animal experiments showed that Qijiaoshengbai capsule significantly increased the levels of white blood cells(P<0.05),and decreased the levels of TNF-αand IL-6 in peripheral blood(P<0.05).The results showed that the active ingredients of Qijiaoshengbai capsule could act on key targets such as TNF-αand IL-6,participate in immune inflammation and other pathways and play a role in the treatment of leukopenia.
作者
杨浩
毛旭文
YANG Hao;MAO Xu-wen(Department of Pharmacy,The Sixth Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China;Pharmacy Teaching and Research Office,Sixth Clinical Medical College,Xinjiang Medical University,Urumqi 830000,China;Department of Pharmacology,School of Pharmacy,Xinjiang Medical University,Urumqi 830017,China)
出处
《云南民族大学学报（自然科学版）》
CAS
2024年第5期543-554,共12页
Journal of Yunnan Minzu University:Natural Sciences Edition
基金
国家自然科学基金(81760749)
新疆维吾尔自治区自然科学基金(2021D01C459)。
